A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-03-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 16.2% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 356 (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placebodouble blindprimarydiagnosis oftreatment of
  Phrases that lowered it: healthychildrenevaluate theto evaluatethe efficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 9.4% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 1031 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 65.8% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 17 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 6568 (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Minimum age: 7 (lowers risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD NCT01371734 · started 2011 · scored riskier than 43% of active trials completed
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder NCT00619619 · started 2008 · scored riskier than 7% of active trials completed
• A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD NCT01371721 · started 2012 · scored riskier than 95% of active trials completed
• Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder NCT00863798 · started 2009 · scored riskier than 21% of active trials completed
• A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD NCT01371708 · started 2012 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.